Avasimibe (BioDeep_00000015344)
代谢物信息卡片
Avasimibe
化学式: C29H43NO4S (501.2912638000001)
中文名称: 阿伐麦布
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)C1=C(C(=CC=C1)C(C)C)OS(=O)(=O)NC(=O)CC2=C(C=C(C=C2C(C)C)C(C)C)C(C)C
InChI: InChI=1S/C29H43NO4S/c1-17(2)22-14-25(20(7)8)27(26(15-22)21(9)10)16-28(31)30-35(32,33)34-29-23(18(3)4)12-11-13-24(29)19(5)6/h11-15,17-21H,16H2,1-10H3,(H,30,31)
描述信息
D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent
Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 μM for ACAT1 and ACAT2, respectively[1]. Avasimibe can be used for the research of prostate cancer[2].
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:177719
- KEGG: C73212
- KEGGdrug: D03012
- PubChem: 166558
- DrugBank: DB06442
- ChEMBL: CHEMBL101309
- CAS: 166518-60-1
- medchemexpress: HY-13215
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zhiquan Wang, Zhe Wang, Miao Lin, Bowen Zheng, Jinlan Zhang. A study on cholesterol-cholesteryl ester metabolic homeostasis and drug intervention in hyperlipidemic hamsters using UHPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2023 Dec; 240(?):115933. doi:
10.1016/j.jpba.2023.115933. [PMID: 38154368] - Peter A C Wing, Nathalie M Schmidt, Rory Peters, Maximilian Erdmann, Rachel Brown, Hao Wang, Leo Swadling, Joseph Newman, Nazia Thakur, Kaho Shionoya, Sophie B Morgan, Timothy Sc Hinks, Koichi Watashi, Dalan Bailey, Scott B Hansen, Andrew D Davidson, Mala K Maini, Jane A McKeating. An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.
PLoS pathogens.
2023 05; 19(5):e1011323. doi:
10.1371/journal.ppat.1011323. [PMID: 37134108] - Juan Bai, Renalison Farias-Pereira, Yuan Zhang, Miran Jang, Yeonhwa Park, Kee-Hong Kim. C. elegans ACAT regulates lipolysis and its related lifespan in fasting through modulation of the genes in lipolysis and insulin/IGF-1 signaling.
BioFactors (Oxford, England).
2020 Sep; 46(5):754-765. doi:
10.1002/biof.1666. [PMID: 32639091] - Jing Pan, Qi Zhang, Katie Palen, Li Wang, Lifen Qiao, Bryon Johnson, Shizuko Sei, Robert H Shoemaker, Ronald A Lubet, Yian Wang, Ming You. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator.
EBioMedicine.
2019 Nov; 49(?):72-81. doi:
10.1016/j.ebiom.2019.10.044. [PMID: 31680003] - Kimiyuki Shibuya, Katsumi Kawamine, Toru Miura, Chiyoka Ozaki, Toshiyuki Edano, Ken Mizuno, Yasunobu Yoshinaka, Yoshihiko Tsunenari. Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors.
Bioorganic & medicinal chemistry.
2018 08; 26(14):4001-4013. doi:
10.1016/j.bmc.2018.06.024. [PMID: 29945757] - Longbo Hu, Jinqian Li, Hua Cai, Wenxia Yao, Jing Xiao, Yi-Ping Li, Xiu Qiu, Huimin Xia, Tao Peng. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
Antiviral research.
2017 Dec; 148(?):5-14. doi:
10.1016/j.antiviral.2017.10.016. [PMID: 29074218] - Palash Pal, Hardik P Gandhi, Ashish M Kanhed, Nirali R Patel, Niraj N Mankadia, Satish N Baldha, Mahesh A Barmade, Prashant R Murumkar, Mange Ram Yadav. Vicinal diaryl azole-based urea derivatives as potential cholesterol lowering agents acting through inhibition of SOAT enzymes.
European journal of medicinal chemistry.
2017 Apr; 130(?):107-123. doi:
10.1016/j.ejmech.2017.02.038. [PMID: 28242547] - Wei Yang, Yibing Bai, Ying Xiong, Jin Zhang, Shuokai Chen, Xiaojun Zheng, Xiangbo Meng, Lunyi Li, Jing Wang, Chenguang Xu, Chengsong Yan, Lijuan Wang, Catharine C Y Chang, Ta-Yuan Chang, Ti Zhang, Penghui Zhou, Bao-Liang Song, Wanli Liu, Shao-cong Sun, Xiaolong Liu, Bo-liang Li, Chenqi Xu. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism.
Nature.
2016 Mar; 531(7596):651-5. doi:
10.1038/nature17412. [PMID: 26982734] - Steve Seung-Young Lee, Junjie Li, Jien Nee Tai, Timothy L Ratliff, Kinam Park, Ji-Xin Cheng. Avasimibe encapsulated in human serum albumin blocks cholesterol esterification for selective cancer treatment.
ACS nano.
2015 Mar; 9(3):2420-32. doi:
10.1021/nn504025a. [PMID: 25662106] - Georges Khoueiry, Mokhtar Abdallah, Faisal Saiful, Nidal Abi Rafeh, Muhammad Raza, Tariq Bhat, Suzanne El-Sayegh, Kamyar Kalantar-Zadeh, James Lafferty. High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.
International urology and nephrology.
2014 Jan; 46(1):27-39. doi:
10.1007/s11255-012-0366-y. [PMID: 23443874] - Keisuke Eguchi, Yukio Fujiwara, Akinori Hayashida, Hasita Horlad, Hikaru Kato, Henki Rotinsulu, Fitje Losung, Remy E P Mangindaan, Nicole J de Voogd, Motohiro Takeya, Sachiko Tsukamoto. Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo.
Bioorganic & medicinal chemistry.
2013 Jul; 21(13):3831-8. doi:
10.1016/j.bmc.2013.04.025. [PMID: 23665143] - Shigehiro Asano, Hitoshi Ban, Kouichi Kino, Katsuhisa Ioriya, Masami Muraoka. Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression.
Bioorganic & medicinal chemistry letters.
2009 Feb; 19(4):1062-5. doi:
10.1016/j.bmcl.2009.01.020. [PMID: 19167888] - Kenji Takahashi, Masayasu Kasai, Masaru Ohta, Yoshimichi Shoji, Kazuyoshi Kunishiro, Mamoru Kanda, Kazuyoshi Kurahashi, Hiroaki Shirahase. Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
Journal of medicinal chemistry.
2008 Aug; 51(15):4823-33. doi:
10.1021/jm800248r. [PMID: 18620381] - Colin Berry, Philippe L L'Allier, Jean Grégoire, Jacques Lespérance, Sylvie Levesque, Reda Ibrahim, Jean-Claude Tardif. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression.
Circulation.
2007 Apr; 115(14):1851-7. doi:
10.1161/circulationaha.106.655654. [PMID: 17389269] - Sharon L Ripp, Jessica B Mills, Odette A Fahmi, Kristen A Trevena, Jennifer L Liras, Tristan S Maurer, Sonia M de Morais. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
Drug metabolism and disposition: the biological fate of chemicals.
2006 Oct; 34(10):1742-8. doi:
10.1124/dmd.106.010132. [PMID: 16837568] - Jean-Claude Tardif, Jean Grégoire, Philippe L L'Allier, Reda Ibrahim, Marc-André Lavoie, Michel LeMay, Eric Cohen, Sylvie Levesque, Pierre-Frédéric Keller, Therese Heinonen, Marie-Claude Guertin. Effect of atherosclerotic regression on total luminal size of coronary arteries as determined by intravascular ultrasound.
The American journal of cardiology.
2006 Jul; 98(1):23-7. doi:
10.1016/j.amjcard.2006.01.052. [PMID: 16784914] - John R Burnett, Dawn E Telford, P Hugh R Barrett, Murray W Huff. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
Biochimica et biophysica acta.
2005 Dec; 1738(1-3):10-8. doi:
10.1016/j.bbalip.2005.11.010. [PMID: 16427354] - Akira Miyazaki, Tomoko Kanome, Takuya Watanabe. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase.
Current drug targets. Cardiovascular & haematological disorders.
2005 Dec; 5(6):463-9. doi:
10.2174/156800605774962040. [PMID: 16503866] - Jean-Claude Tardif, Jean Grégoire, Philippe L L'Allier, Todd J Anderson, Olivier Bertrand, Francois Reeves, Lawrence M Title, Fernando Alfonso, Erick Schampaert, Alita Hassan, Richard McLain, Milton L Pressler, Reda Ibrahim, Jacques Lespérance, John Blue, Therese Heinonen, Josep Rodés-Cabau. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
Circulation.
2004 Nov; 110(21):3372-7. doi:
10.1161/01.cir.0000147777.12010.ef. [PMID: 15533865] - Yves Rival, Nathalie Benéteau, Violaine Chapuis, Thierry Taillandier, Fabrice Lestienne, Elisabeth Dupont-Passelaigue, Jean-François Patoiseau, Francis C Colpaert, Didier Junquéro. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
DNA and cell biology.
2004 May; 23(5):283-92. doi:
10.1089/104454904323090912. [PMID: 15169608] - Frederick J Raal, A David Marais, Ellen Klepack, Jennifer Lovalvo, Richard McLain, Therese Heinonen. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Atherosclerosis.
2003 Dec; 171(2):273-9. doi:
10.1016/j.atherosclerosis.2003.07.011. [PMID: 14644397] - Gemma Llaverías, Juan C Laguna, Marta Alegret. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
Cardiovascular drug reviews.
2003; 21(1):33-50. doi:
. [PMID: 12595916] - Jean-Claude Tardif, Jean Grégoire, Jacques Lespérance, Jean Lambert, Philippe L L'Allier, Josep Rodés, Todd Anderson, John W Blue, James Imus, Therese Heinonen. Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial.
American heart journal.
2002 Oct; 144(4):589-96. doi:
10.1067/mhj.2002.125329. [PMID: 12360153] - Gemma Llaverías, Mireia Jové, Manuel Vázquez-Carrera, Rosa M Sánchez, Cristina Díaz, Gonzalo Hernández, Juan C Laguna, Marta Alegret. Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
European journal of pharmacology.
2002 Sep; 451(1):11-7. doi:
10.1016/s0014-2999(02)02152-0. [PMID: 12223223] - John R Burnett, Murray W Huff. Avasimibe Pfizer.
Current opinion in investigational drugs (London, England : 2000).
2002 Sep; 3(9):1328-33. doi:
". [PMID: 12498009] - Annabelle Rodriguez, David C Usher. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages.
Atherosclerosis.
2002 Mar; 161(1):45-54. doi:
10.1016/s0021-9150(01)00620-7. [PMID: 11882316] - Changiz Taghibiglou, Stephen C Van Iderstine, Agnes Kulinski, Debbie Rudy, Khosrow Adeli. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
Biochemical pharmacology.
2002 Feb; 63(3):349-60. doi:
10.1016/s0006-2952(01)00918-2. [PMID: 11853686] - Eric Bruckert. New advances in lipid-modifying therapies for reducing cardiovascular risk.
Cardiology.
2002; 97(2):59-66. doi:
10.1159/000057673. [PMID: 11978950] - W V Brown. Therapies on the horizon for cholesterol reduction.
Clinical cardiology.
2001 Aug; 24(8 Suppl):III24-7. doi:
10.1002/clc.4960241506. [PMID: 11501600] - W Insull, M Koren, J Davignon, D Sprecher, H Schrott, L M Keilson, A S Brown, C A Dujovne, M H Davidson, R McLain, T Heinonen. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
Atherosclerosis.
2001 Jul; 157(1):137-44. doi:
10.1016/s0021-9150(00)00615-8. [PMID: 11427213] - T M Bocan, B R Krause, W S Rosebury, X Lu, C Dagle, S Bak Mueller, B Auerbach, D R Sliskovic. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
Atherosclerosis.
2001 Jul; 157(1):97-105. doi:
10.1016/s0021-9150(00)00713-9. [PMID: 11427208] - D J Delsing, E H Offerman, W van Duyvenvoorde, H van Der Boom, E C de Wit, M J Gijbels, A van Der Laarse, J W Jukema, L M Havekes, H M Princen. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Circulation.
2001 Apr; 103(13):1778-86. doi:
10.1161/01.cir.103.13.1778. [PMID: 11282910] - D G Robertson, M A Breider, M A Milad. Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Toxicological sciences : an official journal of the Society of Toxicology.
2001 Feb; 59(2):324-34. doi:
10.1093/toxsci/59.2.324. [PMID: 11158726] - T M Bocan, B R Krause, W S Rosebury, S B Mueller, X Lu, C Dagle, T Major, C Lathia, H Lee. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Arteriosclerosis, thrombosis, and vascular biology.
2000 Jan; 20(1):70-9. doi:
10.1161/01.atv.20.1.70. [PMID: 10634802] - S M Post, J P Zoeteweij, M H Bos, E C de Wit, R Havinga, F Kuipers, H M Princen. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat.
Hepatology (Baltimore, Md.).
1999 Aug; 30(2):491-500. doi:
10.1002/hep.510300230. [PMID: 10421659] - J R Burnett, L J Wilcox, D E Telford, S J Kleinstiver, P H Barrett, R S Newton, M W Huff. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Journal of lipid research.
1999 Jul; 40(7):1317-27. doi:
NULL. [PMID: 10393217] - L J Wilcox, P H Barrett, R S Newton, M W Huff. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB.
Arteriosclerosis, thrombosis, and vascular biology.
1999 Apr; 19(4):939-49. doi:
10.1161/01.atv.19.4.939. [PMID: 10195921] - W W Bullen, C D Lathia, R B Abel, R N Hayes. Validated HPLC/MS/MS assay for CI-1011 in rat plasma and a comparison with an HPLC/UV assay.
Journal of pharmaceutical and biomedical analysis.
1998 Sep; 17(8):1399-413. doi:
10.1016/s0731-7085(98)00034-x. [PMID: 9800659] - R J Nicolosi, T A Wilson, B R Krause. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters.
Atherosclerosis.
1998 Mar; 137(1):77-85. doi:
10.1016/s0021-9150(97)00279-7. [PMID: 9568739] - R Ramharack, M A Spahr, C S Sekerke, R L Stanfield, R F Bousley, H T Lee, B K Krause. CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys.
Atherosclerosis.
1998 Jan; 136(1):79-87. doi:
10.1016/s0021-9150(97)00189-5. [PMID: 9544734]